ArticleJACC. Case reports2025
First Human Implant With Cardiac Contractility Modulation in a Patient With an Extravascular Implantable Cardioverter-Defibrillator.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac contractility modulation (CCM) improves myocardial contractility and heart failure (HF) symptoms, whereas the extravascular implantable cardioverter-defibrillator (EV-ICD) offers defibrillation without transvenous leads. Their combined use has not been previously reported. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: This case presents the first documented implantation of CCM therapy in a patient with a prior EV-ICD. Lead placement and programming were optimized to prevent interference. Both devices functioned independently, with stable sensing and no inappropriate therapies. The patient experienced improved HF symptoms. DISCUSSION: This case demonstrates the feasibility and safety of integrating CCM and EV-ICD therapy, highlighting the importance of strategic lead positioning and programming. NOVELTY: This is the first report of CCM and EV-ICD integration, demonstrating their complementary role in HF management. TAKE-HOME MESSAGE: CCM and EV-ICD can be safely combined, expanding options for HF patients requiring both therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.